Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Nelfinavir with Bortezomib in RRMM
NCT03829020Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) and nelfinavir in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 42 days. Started Apr 2019; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)nelfinavir
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03829020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829020.